Evaluating Ultragenyx Pharmaceutical: Insights From 7 Financial Analysts
Evaluating Ultragenyx Pharmaceutical: Insights From 7 Financial Analysts
評估ultragenyx pharmaceutical：來自7位財務分析師的見解
The standing of Ultragenyx Pharmaceutical among...7 analysts have shared their evaluations of Ultragenyx Pharmaceutical (NASDAQ:RARE) during the recent three months, expressing a mix of bullish and bearish perspectives.
在最近三個月內，7位分析師對ultragenyx pharmaceutical (納斯達克：RARE) 進行了評估，表達了看好和看淡的觀點。
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
下表提供了他們最近的評級快照，展示了情緒在過去30天中的演變情況，並將其與之前的月份進行比較。
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $101.29, a high estimate of $116.00, and a low estimate of $73.00. Marking an increase of 3.66%, the current average surpasses the previous average price target of $97.71.
分析師通過對12個月價格目標的評估提供了更深入的見解，顯示平均目標爲101.29美元，高估爲116.00美元，低估爲73.00美元。當前平均目標較上一次的97.71美元目標增長了3.66%。
Interpreting Analyst Ratings: A Closer Look
解讀分析師評級：更深入的了解
The standing of Ultragenyx Pharmaceutical among...
通過對最近分...
登入免費觀看全文
登入/註冊
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間